Headlines about NuVasive (NASDAQ:NUVA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 47.0101356475651 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s scoring:

NuVasive stock opened at $69.38 on Friday. The company has a market capitalization of $3.58 billion, a PE ratio of 36.32, a PEG ratio of 1.91 and a beta of 0.69. NuVasive has a 1 year low of $44.62 and a 1 year high of $71.15.

NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.58. The business had revenue of $281.56 million during the quarter, compared to the consensus estimate of $276.05 million. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. analysts expect that NuVasive will post 2.39 EPS for the current fiscal year.

NUVA has been the subject of a number of research reports. TheStreet raised shares of NuVasive from a “c+” rating to a “b-” rating in a report on Thursday, August 2nd. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a research note on Friday, August 3rd. Zacks Investment Research downgraded NuVasive from a “hold” rating to a “sell” rating in a research note on Tuesday, July 3rd. Needham & Company LLC lowered their price objective on NuVasive from $69.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, August 1st. Finally, Cantor Fitzgerald started coverage on NuVasive in a research note on Thursday, May 31st. They issued a “neutral” rating and a $54.00 price objective for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $64.06.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Recommended Story: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.